Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Transcept Pharmaceuticals, Inc.
POINT RICHMOND, Calif., Feb. 28, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present a general corporate overview at the 33rd Annual Cowen and Company Health Care Conference on March 6, 2013, at 8:00 a.m. Eastern Time.
A live audio webcast of the presentation will be available in the investor relations section of the Transcept website at www.transcept.com, and a replay will be available there for approximately 30 days following the event.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.MyIntermezzo.com.
Contact:
Transcept Pharmaceuticals, Inc.
Leone Patterson
Vice President, Chief Financial Officer
(510) 215-3500
lpatterson@transcept.com
©2012 PR Newswire. All Rights Reserved.
All content © Copyright 2000 - 2013 WorldNow and Toledo News Now, a Raycom Media Station. 
